Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

This study has been completed.
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00065455
First received: July 23, 2003
Last updated: May 7, 2009
Last verified: May 2009
  Purpose

Retinitis pigmentosa (RP) is a collective term for a group of inherited retinal dystrophies that are a major cause of irreversible blindness. RP of some type occurs in approximately 1 out of 3500 persons in the United States(1). Gene mutations are responsible for the majority of RP. To date, mutations have been identified in 30 different genes linked to RP(2). The visual prognosis of RP is poor, since the gradual but relentless visual field loss leads eventually to some degree of blindness(3). Although no effective treatment for RP has been identified, participants supplemented with a daily oral dose of 15,000 IU vitamin A palmitate have shown, on average, a slower rate of deterioration of retinal function when the intervention is continued over several years(4). The purpose of this research is to determine whether administration of high oral doses of vitamin A can acutely improve cone photoreceptor function in RP participants as measured by electroretinography (ERG). In this interventional, non-randomized, prospective, pilot study, 5 participants will receive a daily oral dose of 50,000 IU of vitamin A palmitate for 4 weeks, followed by a maintenance dose of 15,000 IU daily for the subsequent 2 weeks. The primary efficacy outcome is a relative percentage change in ERG response amplitude subsequent to vitamin A supplementation. A secondary efficacy outcome is a relative percentage change in implicit time from pre- to post- vitamin A supplementation, with improvement specified as a shorter response implicit time. Other secondary outcomes will be improvements in visual field (Humphery, 10-2; sum of thresholds). Safety outcomes include visual fields, ETDRS visual acuity, intraocular pressure, serum vitamin A level and liver function tests.


Condition Intervention Phase
Retinitis Pigmentosa
Drug: Vitamin A
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 11
Study Start Date: July 2003
Estimated Study Completion Date: May 2009
Intervention Details:
    Drug: Vitamin A
    N/A
Detailed Description:

Retinitis pigmentosa (RP) is a collective term for a group of inherited retinal dystrophies that are a major cause of irreversible blindness. RP of some type occurs in approximately 1 out of 3500 persons in the United States. Gene mutations are responsible for the majority of RP. To date, mutations have been identified in 30 different genes linked to RP. The visual prognosis of RP is poor, since the gradual but relentless visual field loss leads eventually to some degree of blindness. Although no effective treatment for RP has been identified, participants supplemented with a daily oral dose of 15,000 IU vitamin A palmitate have shown, on average, a slower rate of deterioration of retinal function when the intervention is continued over several years. The purpose of this research is to determine whether administration of high oral doses of vitamin A can acutely improve cone photoreceptor function in RP participants as measured by electroretinography (ERG). In this interventional, non-randomized, prospective, pilot study, 10 participants (five with the RHO1 gene mutation and five without the mutation) will receive a daily oral dose of 50,000 IU of vitamin A palmitate for 4 weeks, followed by a maintenance dose of 15,000 IU daily for the subsequent 2 weeks. The primary efficacy outcome is a relative percentage change in ERG response amplitude subsequent to vitamin A supplementation. A secondary efficacy outcome is a relative percentage change in implicit time from pre- to post- vitamin A supplementation, with improvement specified as a shorter response implicit time. Other secondary outcomes will be improvements in visual field (Humphrey 10-2; sum of thresholds). Safety outcomes include visual fields, ETDRS visual acuity, intraocular pressure, serum vitamin A level and liver function tests.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

All participants must meet the following criteria to participate in the study.

  1. Men and women age 18 years of age and older. (Children will be excluded since there is a higher incidence of vitamin A toxicity in the pediatric population.)
  2. Diagnoses of typical RP of all genetic subtypes (simplex, autosomal dominant, autosomal recessive, and X-linked), as determined primarily by abnormally reduced ERG rod response amplitudes that are relatively more affected than cone ERG amplitudes.
  3. Mutation in the RHO1 gene as determined by genotyping.
  4. Participants in whom flicker ERG can be measured reliably (standard flicker ERG amplitude greater than 2 microV).
  5. Willingness to use contraception for the duration of the study.
  6. Understood and signed consent.

EXCLUSION CRITERIA:

Participants with the following conditions will be excluded from study.

  1. Participants with syndromic RP (i.e., Ushers syndrome).
  2. Have abnormal liver function (greater than ULN ALT, AST, Alkaline Phosphate, or Total Bilirubin).
  3. Hematocrit greater than 1.5 x ULN
  4. Have abnormal kidney function (greater than1.5 mg/dL serum creatinine).
  5. Currently or has taken greater than 15,000 IU/day vitamin A supplementation within 6 months of the first screening visit.
  6. Is pregnant or lactating (due to evidence that sugests excessive intake of vitamin A could be tertogenic in humans and affect the content of breast milk).
  7. Currently or has taken greater than 400 IU/day of vitamin E supplementation within 6 months of enrollment.
  8. Vitamin A serum level exceeding 150 microg/dL.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00065455

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00065455     History of Changes
Other Study ID Numbers: 030255, 03-EI-0255
Study First Received: July 23, 2003
Last Updated: May 7, 2009
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Retinitis Pigmentosa
Vitamin A
ERG
RP

Additional relevant MeSH terms:
Retinitis Pigmentosa
Retinitis
Retinal Diseases
Eye Diseases
Eye Diseases, Hereditary
Retinal Dystrophies
Retinal Degeneration
Genetic Diseases, Inborn
Vitamin A
Vitamins
Retinol palmitate
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Antioxidants
Molecular Mechanisms of Pharmacological Action
Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 28, 2014